Patent · US Active

Genetically modified TFPI and method of treating coagulation using the same

US8912143B2 · kind B2 · utility

0Cited by

0References

4Claims

0Family size

Assignee

FUDAN UNIVERSITY · CN

Inventors

Duan Ma · Shanghai, CN
Jingui Mu · Shanghai, CN
Jiping Wang · Sharonville, US
Huijun Wang · Beijing, CN
Wang Liang · Shanghai, CN

Key dates

Filing date	Nov 16, 2011
Grant date	Dec 16, 2014
Priority date	—
Expiry date	Jan 20, 2033

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P7/02
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides long half life genetically modified TFPI sequences (LTFPI) for anticoagulation. On the genetically modified TFPI sequence, the lysine at the carboxy-terminal sites 241, 254, 260 and 261 are replaced by alanin and the amino acid asparagine at glycosylation sites 117, 167, 228 and the amino acids serine and threonine at glycosylation sites 174 and 175 are substitutionally mutated. The present invention also provides methods of making the LTFPI through high efficient LTFPI expression from yeast production system.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.